Vermillion shares up 22% on positive ovarian cancer Dx study results
This article was originally published in Clinica
Executive Summary
Diagnostics specialist Vermillion has seen its share price rise by 22% after a clinical study found that its ovarian cancer blood test, OVA1, had a sensitivity of 98%. Vermillion co-developed the test with Quest Diagnostics.